- Home
- COLL vs UDMY Comparison
COLL vs UDMY Comparison
Compare COLL & UDMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- UDMY
- Stock Information
- Founded
- COLL 2002
- UDMY 2009
- Country
- COLL United States
- UDMY United States
- Employees
- COLL N/A
- UDMY N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- UDMY Other Consumer Services
- Sector
- COLL Health Care
- UDMY Real Estate
- Exchange
- COLL Nasdaq
- UDMY Nasdaq
- Market Cap
- COLL 910.2M
- UDMY 904.2M
- IPO Year
- COLL 2015
- UDMY 2021
- Fundamental
- Price
- COLL $26.79
- UDMY $6.96
- Analyst Decision
- COLL Strong Buy
- UDMY Buy
- Analyst Count
- COLL 5
- UDMY 11
- Target Price
- COLL $43.60
- UDMY $10.30
- AVG Volume (30 Days)
- COLL 393.2K
- UDMY 1.3M
- Earning Date
- COLL 05-08-2025
- UDMY 04-30-2025
- Dividend Yield
- COLL N/A
- UDMY N/A
- EPS Growth
- COLL 43.56
- UDMY N/A
- EPS
- COLL 1.86
- UDMY N/A
- Revenue
- COLL $631,449,000.00
- UDMY $786,565,000.00
- Revenue This Year
- COLL $19.96
- UDMY $2.96
- Revenue Next Year
- COLL $3.93
- UDMY $5.52
- P/E Ratio
- COLL $14.31
- UDMY N/A
- Revenue Growth
- COLL 11.41
- UDMY 7.91
- 52 Week Low
- COLL $23.23
- UDMY $5.68
- 52 Week High
- COLL $42.29
- UDMY $11.60
- Technical
- Relative Strength Index (RSI)
- COLL 43.80
- UDMY 48.85
- Support Level
- COLL $25.87
- UDMY $5.87
- Resistance Level
- COLL $27.95
- UDMY $6.94
- Average True Range (ATR)
- COLL 1.50
- UDMY 0.41
- MACD
- COLL 0.05
- UDMY 0.13
- Stochastic Oscillator
- COLL 69.33
- UDMY 100.00
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.